These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 21830958

  • 1. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH, Annas GJ.
    N Engl J Med; 2011 Aug 25; 365(8):681-3. PubMed ID: 21830958
    [No Abstract] [Full Text] [Related]

  • 2. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB.
    Yale J Health Policy Law Ethics; 2012 Aug 25; 12(2):209-63. PubMed ID: 23175916
    [No Abstract] [Full Text] [Related]

  • 3. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ.
    N Engl J Med; 2009 Sep 17; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract] [Full Text] [Related]

  • 4. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC.
    Cornell Law Rev; 2008 Jul 17; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract] [Full Text] [Related]

  • 5. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM, Curfman GD.
    N Engl J Med; 2013 Aug 22; 369(8):696-7. PubMed ID: 23923990
    [No Abstract] [Full Text] [Related]

  • 6. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM, Curfman G.
    JAMA; 2018 Aug 14; 320(6):547-548. PubMed ID: 30039167
    [No Abstract] [Full Text] [Related]

  • 7. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS, Studdert DM.
    N Engl J Med; 2009 Feb 05; 360(6):559-61. PubMed ID: 19196672
    [No Abstract] [Full Text] [Related]

  • 8. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM, Curry JA.
    Tort Trial Insur Pract Law J; 2007 Feb 05; 43(1):35-70. PubMed ID: 18354866
    [No Abstract] [Full Text] [Related]

  • 9. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH.
    Food Drug Law J; 2007 Feb 05; 62(2):399-422. PubMed ID: 17632969
    [No Abstract] [Full Text] [Related]

  • 10. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk, responsibility, and generic drugs.
    Kesselheim AS, Avorn J, Greene JA.
    N Engl J Med; 2012 Nov 01; 367(18):1679-81. PubMed ID: 23113477
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A.
    Rev Law Soc Change; 2012 Nov 01; 35(4):793-862. PubMed ID: 22363960
    [Abstract] [Full Text] [Related]

  • 17. Pharmaceutical promotion and First Amendment rights.
    Troy DE, Gottlieb S.
    N Engl J Med; 2008 Jul 31; 359(5):536; author reply 536-7. PubMed ID: 18669437
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M.
    Seton Hall Law Rev; 2007 Jul 31; 37(4):941-68. PubMed ID: 18363218
    [No Abstract] [Full Text] [Related]

  • 20. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC.
    Food Drug Law J; 2010 Jul 31; 65(2):247-83, i-ii. PubMed ID: 24475542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.